Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Feline Enfeksiyöz Peritonitis ve COVID-19 Arasındaki Benzerlik ve Farklılıklar: Geleneksel Derleme
Similarities and Differences Between Feline Infectious Peritonitis and COVID-19: Traditional Review
Mutlu SEVİNÇa, Mahmut OKa, Merve İDERa
aSelçuk Üniversitesi Veteriner Fakültesi, İç Hastalıkları ABD, Konya, Türkiye
Turkiye Klinikleri J Vet Sci. 2022;13(2):58-71
doi: 10.5336/vetsci.2021-83092
Article Language: TR
Full Text
ÖZET
 Koronavirüsler [coronaviruses (CoVs)], insan ve hayvanlarda ciddi hastalıklara ve salgınlara sebep olmaktadır. Günümüzde hâlen etkinliğini sürdüren şiddetli akut solunum sendromu-CoV-2 [severe acute respiratory syndrome-CoV-2 (SARS-CoV-2)], tüm dünyanın yaşam tarzında köklü değişikliklere sebep olmasının yanı sıra sağlık sistemleri ve finansman üzerine de ciddi sonuçlar doğurmuştur. İnsanlarda SARS-CoV-2'nin biyolojisi ve patogenezi ile ilgili son 1 yıldır kapsamlı ve detaylı araştırmalar yapılmakta, hastalığın önlenmesi ve tedavisinde yeni stratejiler geliştirilmeye çalışılmaktadır. CoV'ların 1930'lu yıllardan beri çeşitli hayvan türlerinde respiratorik, gastrointestinal, hepatik, nörolojik ve renal hastalıklara sebep olduğu bilinmektedir. Feline enfeksiyöz peritonitis, patojenik kedi CoV'larının neden olduğu bir hastalıktır. Bu hastalık, granülomatöz lezyonlar (kuru veya nonefüzif form) ya da vücut boşluklarında efüzyon oluşumuna sebep olan vaskülitis (ıslak veya efüzif form) ile karakterizedir. Kedilerin enfeksiyöz peritonitisi, veteriner hekimlik alanında iyi bilinmesine rağmen hekimler için hâlen insanlardaki koronavirüs hastalığı-2019 gibi tedavide zorluk yaratan ve esrarengiz bir hastalık olmasının yanı sıra kedi sahipleri için de üzücü ve kahredici bir tanı olmaya devam etmektedir. Feline enfeksiyöz peritonitisin ortaya çıktığı son 40 yılı aşkın bir süredir patogenezi, teşhisi ve tedavisini geliştirme çabaları için çok sayıda araştırma yapılmış ve yapılmaya da devam etmektedir. Bu derleme, hâlen gizemini koruyan SARS-CoV-2 ve kedi CoV enfeksiyonları arasındaki olası benzerlikler ve farklılıkların ortaya konarak, yapılacak araştırmaların muhtemel tartışma noktalarına katkı sağlaması amacıyla ele alındı.

Anahtar Kelimeler: Koronavirüs; feline enfeksiyöz peritonitis; SARS-CoV-2
ABSTRACT
 Coronaviruses (CoVs) have caused serious diseases and epidemics in humans and animals. Severe acute respiratory syndromeCoV-2 (SARS-CoV-2), which is still ongoing today, has caused serious changes in the life style of the world, as well as serious consequences on health systems and finances. For the last 1 year, comprehensive and detailed research has been carried out on the biology and pathogenesis of SARS-CoV-2 in humans, and new strategies are tried to be developed for the prevention and treatment of the disease. It has been known that CoVs cause respiratory, gastrointestinal, hepatic, neurological and renal diseases in various animal species since the 1930s. Feline infectious peritonitis is a disease caused by pathogenic feline CoVs. This disease is characterized by granulomatous lesions (dry or non-effusive form) or vasculitis (wet or effusive form) that causes effusion in body cavities. Although feline infectious peritonitis is well known in veterinary medicine, it is still a frustrating and mysterious disease like coronavirus disease-2019 for physicians, and continues to be a sad and overwhelming diagnosis for owners. For more than 40 years, a great deal of research has been done and continues to be done for the pathogenesis, diagnosis and treatment of feline infectious peritonitis in cats. This review is discussed to reveal the possible similarities and differences between SARS-CoV-2 and feline CoV infections, which are still surprising and remain mysterious, and to contribute to possible discussion points for research on human and feline CoVs.

Keywords: Coronavirus; feline infectious peritonitis; SARS-CoV-2
REFERENCES:
  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3. [Link] 
  2. Maden M. COVID-19 pandemisi: sağlık iletişimi, tek sağlık ve biyogüvenlik [COVID-19 pandemic: health communication, one health and biosecurity]. Turkiye Klinikleri J Vet Sci. 2020;11(2):81-91. [Crossref] 
  3. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. Erratum in: Lancet Respir Med. 2020. [Crossref]  [PubMed]  [PMC] 
  4. Cyranoski D. Profile of a killer: the complex biology powering the coronavirus pandemic. Nature. 2020;581(7806):22-6. [Crossref]  [PubMed] 
  5. Paltrinieri S, Giordano A, Stranieri A, Lauzi S. Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): Are they similar? Transbound Emerg Dis. 2020:10.1111/tbed.13856. [Crossref]  [PubMed]  [PMC] 
  6. Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, Guan Y. Evolutionary insights into the ecology of coronaviruses. J Virol. 2007;81(8):4012-20. Erratum in: J Virol. 2007;81(15):8371. [Crossref]  [PubMed]  [PMC] 
  7. Pedersen NC, Eckstrand C, Liu H, Leutenegger C, Murphy B. Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. Vet Microbiol. 2015;175(2-4):157-66. [Crossref]  [PubMed]  [PMC] 
  8. Legendre AM, Kuritz T, Galyon G, Baylor VM, Heidel RE. Polyprenyl immunostimulant treatment of cats with presumptive non-effusive feline infectious peritonitis in a field study. Front Vet Sci. 2017;4:7. [Crossref]  [PubMed]  [PMC] 
  9. Kennedy MA. Feline infectious peritonitis: update on pathogenesis, diagnostics, and treatment. Vet Clin North Am Small Anim Pract. 2020;50(5):1001-11. [Crossref]  [PubMed] 
  10. Zhang Q, Zhang H, Huang K, Yang Y, Hui X, Gao J, et al. SARS-CoV-2 neutralizing serum antibodies in cats: A serological investigation. bioRxiv. 2020. [Crossref] 
  11. Lau SY, Wang P, Mok BW, Zhang AJ, Chu H, Lee AC, et al. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg Microbes Infect. 2020;9(1):837-42. [Crossref]  [PubMed]  [PMC] 
  12. Chen J, Huang C, Zhang Y, Zhang S, Jin M. Severe acute respiratory syndrome coronavirus 2-specific antibodies in pets in Wuhan, China. J Infect. 2020;81(3):e68-9. [Crossref]  [PubMed]  [PMC] 
  13. Chaw SM, Tai JH, Chen SL, Hsieh CH, Chang SY, Yeh SH, et al. The origin and underlying driving forces of the SARS-CoV-2 outbreak. J Biomed Sci. 2020;27(1):73. [Crossref]  [PubMed]  [PMC] 
  14. Malaiyan J, Arumugam S, Mohan K, Gomathi Radhakrishnan G. An update on the origin of SARS-CoV-2: Despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and O-linked glycan residues. J Med Virol. 2021;93(1):499-505. [Crossref]  [PubMed]  [PMC] 
  15. MacLachlan NJ, Dubovi EJ. Fenner's Veterinary Virology. 4th ed. San Diego: Elsevier; 2010. [Link] 
  16. Herrewegh AA, Smeenk I, Horzinek MC, Rottier PJ, de Groot RJ. Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol. 1998;72(5):4508-14. [Crossref]  [PubMed]  [PMC] 
  17. Takano T, Wakayama Y, Doki T. Endocytic pathway of feline coronavirus for cell entry: differences in serotype-dependent viral entry pathway. Pathogens. 2019;8(4):300. [Crossref]  [PubMed]  [PMC] 
  18. Addie DD. Feline infectious peritonitis: Answers to frequently asked questions concerning FIP and coronavirus. Vet Nurs J. 2019;34(8):201-6. [Crossref]  [PMC] 
  19. Wang M, Li M, Ren R, Li L, Chen EQ, Li W, et al. International expansion of a novel SARS-CoV-2 mutant. J Virol. 2020;94(12):e00567-20. [Crossref]  [PubMed]  [PMC] 
  20. Lin XD, Wang W, Hao ZY, Wang ZX, Guo WP, Guan XQ, et al. Extensive diversity of coronaviruses in bats from China. Virology. 2017;507:1-10. [Crossref]  [PubMed]  [PMC] 
  21. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81. [Crossref]  [PubMed]  [PMC] 
  22. OIE [İnternet]. Copyright © OIE 2022 [Erişim tarihi: 02 Kasım 2022]. Covid 19. Events in animals. Erişim linki: [Link] 
  23. Garigliany M, Van Laere AS, Clercx C, Giet D, Escriou N, Huon C, et al. SARS-CoV-2 natural transmission from human to cat, Belgium, March 2020. Emerg Infect Dis. 2020;26(12):3069-71. [Crossref]  [PubMed]  [PMC] 
  24. Barrs VR, Peiris M, Tam KWS, Law PYT, Brackman CJ, To EMW, et al. SARS-CoV-2 in quarantined domestic cats from COVID-19 households or close contacts, Hong Kong, China. Emerg Infect Dis. 2020;26(12):3071-4. [Crossref]  [PubMed]  [PMC] 
  25. Newman A, Smith D, Ghai RR, Wallace RM, Torchetti MK, Loiacono C, et al. First reported cases of SARS-CoV-2 infection in companion animals - New York, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):710-3. [Crossref]  [PubMed]  [PMC] 
  26. ProMED [İnternet]. © 2021 International Society for Infectious Diseases [Erişim tarihi: 28 Ocak 2021]. COVID-19 update (181): Germany (BY), France (AC), cat, OIE animal case defin. 2020. Erişim linki: [Link] 
  27. Hossain MG, Javed A, Akter S, Saha S. SARS-CoV-2 host diversity: An update of natural infections and experimental evidence. J Microbiol Immunol Infect. 2021;54(2):175-81. [Crossref]  [PubMed]  [PMC] 
  28. Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, et al. Virology: SARS virus infection of cats and ferrets. Nature. 2003;425(6961):915. [Crossref]  [PubMed]  [PMC] 
  29. Pedersen NC. An update on feline infectious peritonitis: virology and immunopathogenesis. Vet J. 2014;201(2):123-32. [Crossref]  [PubMed]  [PMC] 
  30. Kim SJ, Nguyen VG, Park YH, Park BK, Chung HC. A novel synonymous mutation of SARS-CoV-2: is this possible to affect their antigenicity and immunogenicity? Vaccines (Basel). 2020;8(2):220. [Crossref]  [PubMed]  [PMC] 
  31. WHO [İnternet]. © 2022 WHO [Erişim tarihi: 02 Kasım 2022]. Tracking SARS-CoV-2 variants. Erişim linki: [Link] 
  32. Public Health England [İnternet]. © Crown copyright [Erişim tarihi: 02 Kasım 2022]. Investigation of novel SARS-CoV-2 variant, variant of concern. 2020. Erişim linki: [Link] 
  33. Ferasin L, Fritz M, Ferasin H, Becquart P, Legros V, Leroy EM. Myocarditis in naturally infected pets with the British variant of COVID-19. bioRxiv. 2021. [Crossref] 
  34. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502. [Crossref]  [PubMed]  [PMC] 
  35. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238-44. [Crossref]  [PubMed]  [PMC] 
  36. Roussel Y, Giraud-Gatineau A, Jimeno MT, Rolain JM, Zandotti C, Colson P, et al. SARS-CoV-2: fear versus data. Int J Antimicrob Agents. 2020;55(5):105947. [Crossref]  [PubMed]  [PMC] 
  37. Addie DD, Toth S, Murray GD, Jarrett O. Risk of feline infectious peritonitis in cats naturally infected with feline coronavirus. Am J Vet Res. 1995;56(4):429-34. [PubMed] 
  38. Addie D, Belák S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T, et al. Feline infectious peritonitis. ABCD guidelines on prevention and management. J Feline Med Surg. 2009;11(7):594-604. [Crossref]  [PubMed]  [PMC] 
  39. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg. 2009;11(4):225-58. [Crossref]  [PubMed]  [PMC] 
  40. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-90. [Crossref]  [PubMed]  [PMC] 
  41. Luan J, Lu Y, Jin X, Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020;526(1):165-9. [Crossref]  [PubMed]  [PMC] 
  42. Van Hamme E, Desmarets L, Dewerchin HL, Nauwynck HJ. Intriguing interplay between feline infectious peritonitis virus and its receptors during entry in primary feline monocytes. Virus Res. 2011;160(1-2):32-9. [Crossref]  [PubMed]  [PMC] 
  43. Cipriano M, Ruberti E, Giacalone A. Gastrointestinal infection could be new focus for coronavirus diagnosis. Cureus. 2020;12(3):e7422. [Crossref]  [PubMed]  [PMC] 
  44. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50-4. [Crossref]  [PubMed]  [PMC] 
  45. Barker EN, Stranieri A, Helps CR, Porter EL, Davidson AD, Day MJ, et al. Limitations of using feline coronavirus spike protein gene mutations to diagnose feline infectious peritonitis. Vet Res. 2017;48(1):60. [Crossref]  [PubMed]  [PMC] 
  46. Olsen CW, Corapi WV, Jacobson RH, Simkins RA, Saif LJ, Scott FW. Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity. J Gen Virol. 1993;74(Pt 4):745-9. [Crossref]  [PubMed] 
  47. Peron JPS, Nakaya H. Susceptibility of the elderly to SARS-CoV-2 infection: ACE-2 overexpression, shedding, and antibody-dependent enhancement (ADE). Clinics (Sao Paulo). 2020;75:e1912. [Crossref]  [PubMed]  [PMC] 
  48. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72-3. [Crossref]  [PubMed]  [PMC] 
  49. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-74. [Crossref]  [PubMed]  [PMC] 
  50. Chu H, Chan JF, Wang Y, Yuen TT, Chai Y, Hou Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020;71(6):1400-9. [Crossref]  [PubMed]  [PMC] 
  51. Merad M, Martin JC. Author correction: pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(7):448. Erratum for: Nat Rev Immunol. 2020;20(6):355-62. [Crossref]  [PubMed]  [PMC] 
  52. Acar DD, Olyslaegers DAJ, Dedeurwaerder A, Roukaerts IDM, Baetens W, Van Bockstael S, et al. Upregulation of endothelial cell adhesion molecules characterizes veins close to granulomatous infiltrates in the renal cortex of cats with feline infectious peritonitis and is indirectly triggered by feline infectious peritonitis virus-infected monocytes in vitro. J Gen Virol. 2016;97(10):2633-42. [Crossref]  [PubMed] 
  53. Rossi G, Cornaro C, Battilani M, Pocacqua V, Paltrinieri S. Production of IFN-γ in feline whole blood after incubation with potential T-cell epitopes of the nucleocapsid protein of feline coronavirus. Vet Microbiol. 2011;150(3-4):248-56. [Crossref]  [PubMed]  [PMC] 
  54. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. [PubMed]  [PMC] 
  55. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients With COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-9. [Crossref]  [PubMed]  [PMC] 
  56. Mahase E. Covid-19: concerns grow over inflammatory syndrome emerging in children. BMJ. 2020;369:m1710. [Crossref]  [PubMed] 
  57. Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. [Crossref]  [PubMed]  [PMC] 
  58. Pedersen NC. An update on feline infectious peritonitis: diagnostics and therapeutics. Vet J. 2014;201(2):133-41. [Crossref]  [PubMed]  [PMC] 
  59. Stranieri A, Giordano A, Paltrinieri S, Giudice C, Cannito V, Lauzi S. Comparison of the performance of laboratory tests in the diagnosis of feline infectious peritonitis. J Vet Diagn Invest. 2018;30(3):459-63. [Crossref]  [PubMed]  [PMC] 
  60. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552-5. [Crossref]  [PubMed]  [PMC] 
  61. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518-9. [Crossref]  [PubMed]  [PMC] 
  62. Addie DD, Jarrett O. Use of a reverse-transcriptase polymerase chain reaction for monitoring the shedding of feline coronavirus by healthy cats. Vet Rec. 2001;148(21):649-53. [Crossref]  [PubMed] 
  63. Bálint Á, Farsang A, Szeredi L, Zádori Z, Belák S. Recombinant feline coronaviruses as vaccine candidates confer protection in SPF but not in conventional cats. Vet Microbiol. 2014;169(3-4):154-62. [Crossref]  [PubMed]  [PMC] 
  64. Day MJ, Horzinek MC, Schultz RD, Squires RA; Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). WSAVA Guidelines for the vaccination of dogs and cats. J Small Anim Pract. 2016;57(1):E1-45. [Crossref]  [PubMed]  [PMC] 
  65. Saif LJ. Vaccines for COVID-19: Perspectives, prospects, and challenges based on candidate SARS, MERS, and animal coronavirus vaccines. Europ Med J. 2020. [Crossref] 
  66. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854-87. [Crossref]  [PubMed]  [PMC] 
  67. Hartmann K, Ritz S. Treatment of cats with feline infectious peritonitis. Vet Immunol Immunopathol. 2008;123(1-2):172-5. [Crossref]  [PubMed]  [PMC] 
  68. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020;83(6):534-6. [Crossref]  [PubMed]  [PMC] 
  69. Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018;219:226-33. [Crossref]  [PubMed]  [PMC] 
  70. Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg. 2018;20(4):378-92. [Crossref]  [PubMed]  [PMC] 
  71. Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019;21(4):271-81. [Crossref]  [PubMed]  [PMC] 
  72. Nili A, Farbod A, Neishabouri A, Mozafarihashjin M, Tavakolpour S, Mahmoudi H. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Rev Med Virol. 2020;30(6):1-13. [Crossref]  [PubMed] 
  73. Ledford H. Hopes rise for coronavirus drug remdesivir. Nature. 2020. [Crossref]  [PubMed] 
  74. Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020;35:101647. [Crossref]  [PubMed]  [PMC] 
  75. Addie DD, Curran S, Bellini F, Crowe B, Sheehan E, Ukrainchuk L, et al. Oral Mutian®X stopped faecal feline coronavirus shedding by naturally infected cats. Res Vet Sci. 2020;130:222-9. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com